# Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma

> **NCT04987944** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 45 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Zavegepant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04987944
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-18
- **Primary completion:** 2023-03-29
- **Final completion:** 2023-04-04
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns.
- **Last updated:** 2024-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04987944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04987944, "Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04987944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*